Advertisement

Clinical Presentation and Treatment

  • Max J. Coppes
  • Christine Campbell
  • Bryan R. G. Williams
Part of the Molecular Biology Intelligence Unit book series (MBIU)

Abstract

In the past two decades, there has been a considerable improvement in the understanding and management of Wilms tumor and other primary renal childhood malignancies. Wilms tumor is usually diagnosed in children under the age of six, although occasionally older children are affected. Current treatment for Wilms tumor includes surgery and chemotherapy for all patients and radiation therapy for those with advanced disease or specific adverse prognostic features. This has led to cure rates exceeding 80%,1 permitting most affected children to reach adulthood.

Keywords

Genitourinary Malformation Drash Syndrome Natl Cancer Lnst WAGR Syndrome Mulibrey Nanism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Green DM, D’Angio GJ, Beckwith JB, Breslow N, Finklestein J, Kelalis P, Thomas P: Wilms’ tumor (Nephroblastoma, renal embryoma). In: Pizzo PA and Poplack DG (eds): Principles and Practice of Pediatric Oncology. Philadelphia: J B Lippincott Company, 1993: 713–737.Google Scholar
  2. 2.
    Clericuzio CL: Clinical phenotypes and Wilms tumor. Med and Pediatr Oncol, 1993; 21: 182–187.CrossRefGoogle Scholar
  3. 3.
    Clericuzio CL, D’Angio GJ, Duncan M, Green DM, Knudson Jr AG: Summary and recommendations of the workshop held at the first international conference on molecular and clinical genetics of childhood renal tumors, Albuquerque, New Mexico, May 14–16, 1992. Med Pediatr Oncol 1993; 21: 233–236.Google Scholar
  4. 4.
    Breslow N, Olshan A, Beckwith JB, Green DM: Epidemiology of Wilms tumor. Med Pediatr Oncol 1993; 21: 172–181.PubMedCrossRefGoogle Scholar
  5. 5.
    Stiller CA, Parkin DM: International variations in the incidence of childhood renal tumours. Br J Cancer 1990; 62: 1026–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Coppes MJ: Wilms tumor: A compilation of clinical and molecular characteristics. PhD thesis Amsterdam, 1992.Google Scholar
  7. 7.
    Kramer S, Meadows AT, Jarrett P: Racial variation in incidence of Wilms’ tumor: relationship to congenital anomalies. Med Pediatr Oncol 1984; 12: 401–405.PubMedCrossRefGoogle Scholar
  8. 8.
    Breslow NE, Langholz B- Childhood cancer incidence: Geographical and temporal variations. Int J Cancer 1983; 32: 703–716.PubMedCrossRefGoogle Scholar
  9. 9.
    Arrigo S, Beckwith JB, Sharples K, D’Angio G, Haase G: Better survival after combined modality care for adults with Wilms’ tumor. A report from the National Wilms’ Tumor Study. Cancer 1990; 66: 827–830.PubMedCrossRefGoogle Scholar
  10. 10.
    Breslow N, Beckwith JB, Ciol M, Sharples K: Age distribution of Wilms’ tumor: Report from the National Wilms’ Tumor Study. Cancer Res 1988; 48: 1653–1657.PubMedGoogle Scholar
  11. 11.
    Pastore G, Carli M, Lemerle J, Tournade MF, Voûte PA, Rey A, Burgers JMV, Zucker JM, Bürger D, De Kraker J, Delemarre JFM: Epidemiological features of Wilms’ tumor: Results of studies by the International Society of Paediatric Oncology (SIOP). Med Pediatr Oncol 1988; 16: 7–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Coppes MJ, De Kraker J, Van Dijken PJ, Perry HJ, Delemarre JF, Tournade MF, Lemerle J, Voûte PA: Bilateral Wilms’ tumor: Longterm survival and some epidemiological features. J Clin Oncol 1989; 7: 310–315.PubMedGoogle Scholar
  13. 13.
    Shearer P, Parham DM, Fontanesi J, Kumar M, Lobe TE, Fairclough D, Douglass EC, Wilimas J: Bilateral Wilms tumor. Cancer 1993; 72: 1422–1426.PubMedCrossRefGoogle Scholar
  14. 14.
    Knudson AG, Strong LC: Mutation and cancer: A model for Wilms’ tumor of kidney. J Natl Cancer Inst 1972; 48: 313–324.PubMedGoogle Scholar
  15. 15.
    Bunin GR, Kramer S, Marrero O, Meadows AT: Gestational risk factors for Wilms’ tumor: Results of a case-control study. Cancer Res 1987; 47: 2972–2977.PubMedGoogle Scholar
  16. 16.
    Bunin GR, Nass CC, Kramer S, Meadows AT: Parental occupation and Wilms’ tumor: Results of a case-control study. Cancer Res 1989; 49: 725–729.PubMedGoogle Scholar
  17. 17.
    Coppes MJ: Serum biological markers and paraneoplastic syndromes in Wilms tumor. Med Pediatr Oncol 1993; 21: 213–221.PubMedCrossRefGoogle Scholar
  18. 18.
    Green DM: Diagnosis and management of malignant solid tumors in infants and children. Boston: Martinus Nijhoff Publishing, 1985.Google Scholar
  19. 19.
    Coppes MJ, Zandvoort SW, Sparling CR, Poon AO, Weitzman S, Blanchette VS: Acquired von Willebrand disease in Wilms’ tumor patients. J Clin Oncol 1992; 10: 422–427.PubMedGoogle Scholar
  20. 20.
    Kenny GM, Mirand EA, Staubitz WJ, Allen JE, Trudel PJ, Murphy GP: Erythropoietin levels in Wilms tumor patients. J Urol 1970; 104: 758–761.PubMedGoogle Scholar
  21. 21.
    Murphy GP, Allen JE, Staubitz WJ, Sinks LF, Mirand EA: Erythropoietin levels in patients with Wilms tumor. Follow-up evaluation. NY State J Med 1972; 72: 487–489.Google Scholar
  22. 22.
    Tsuchida Y, Mochida Y, Kamii Y, Honna T, Sacks M, Hata J, Yokoyama T, Sasaki F, Nishiura M, Takeda K, et al: Determination of plasma total renin level by RIA with a monoclonal antibody: value as a marker for nephroblastoma. J Pediatr Surg 1990; 25: 1092–1094.PubMedCrossRefGoogle Scholar
  23. 23.
    Tsuchida Y, Yokomori K, Nishiuria M, Shimizu K: Total renin as a marker for pediatric tumours. Med Pediatr Oncol 1993; 21: 603.Google Scholar
  24. 24.
    Kumar S, West DC, Ponting JM, Gattamaneni HR: Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer 1989; 44: 445–448.PubMedCrossRefGoogle Scholar
  25. 25.
    Longaker MT, Adzick NS, Sadigh D, Hendin B, Stair SE, Duncan BW, Harrison MR, Spendlove R, Stern R Hyaluronic acid-stimulating activity in the pathophysiology of Wilms’ tumors. J Natl Cancer Inst 1990; 82: 135–139.PubMedCrossRefGoogle Scholar
  26. 26.
    Stern M, Longaker MT, Adzick NS, Harrison MR, Stern R: Hyaluronidase levels in urine from Wilms’ tumor patients. J Natl Cancer Inst 1991; 83: 1569–1574.PubMedCrossRefGoogle Scholar
  27. 27.
    D’Angio GJ, Rosenberg H, Sharples K, Kelalis P, Breslow N, Green DM: Position paper: Imaging methods for primary renal tumors of childhood: Costs versus benefits. Med Pediatr Oncol 1993; 21: 205–212.PubMedCrossRefGoogle Scholar
  28. 28.
    Thomas PR, Shochat SJ, Norkool P, Beckwith JB, Breslow NE, D’Angio GJ: Prognostic implications of hepatic adhesion, invasion, and metastases at diagnosis of Wilms’ tumor. The National Wilms’ Tumor Study Group. Cancer 1991; 68: 2486–2488.PubMedCrossRefGoogle Scholar
  29. 29.
    Ritchey ML, Othersen HJ, De Lorimier A, Kramer SA, Benson C, Kelalis PP: Renal vein involvement with nephroblastoma: A report of the National Wilms’ Tumor Study-3. Eur Urol 1990; 17: 139–144.PubMedGoogle Scholar
  30. 30.
    Beahrs OH, Henson DE, Hutter RVP, Myers MH: Manual for staging of cancer. Philadelphia: JB Lippincott Company, 1988.Google Scholar
  31. 31.
    Tournade MF, Com-Nougué C, Voûte PA, Lemerle J, De Kraker J, Delemarre JFM, Burgers M, Habrand JL, Moorman CGM, Bürger D, Rey A, Zucker JM, Carli M, Jereb B, Bey P, Gauthier F, Sandstedt B: Results of the sixth International Society of Pediatric Oncology Wilms’ tumor trial and study: A risk-adapted therapeutic approach in Wilms’ tumor. J Clin Oncol 1993; 11: 1014–1023.PubMedGoogle Scholar
  32. 32.
    Ladd WE, White RR: Embryoma of the kidney (Wilms’ tumor). JAMA 1941; 117: 1858–1862.CrossRefGoogle Scholar
  33. 33.
    Ehrlich RM: Complications of Wilms’tumor surgery. Urol Clin North Amer 1983; 10: 399–406.Google Scholar
  34. 34.
    D’Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Faigl P, Goodwin W, Leape LL, Sinks LF, Sutow W, Tefft M, Wolff J: The treatment of Wilms’ tumor. Results from the National Wilms’ Tumor Study. Cancer 1976; 38: 633–646.PubMedCrossRefGoogle Scholar
  35. 35.
    Lemerle J, Voûte PA, Tournade MF, Rodary C, Delemarre JFM, Sarrazin D, Burgers JMV, Sandstedt B, Middenberger H, Carli M, Jereb B, C.G.M. M-V: Effectiveness of preoperative chemotherapy in Wilms’ tumor: Results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983; 10: 604–609.Google Scholar
  36. 36.
    D’Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, DeLorimier A, Fernbach D, Hrabovsky E, Jones B, Kelalis P, Othersen B, Tefft M, Thomas PRM: Treatment of Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer 1989; 64: 349–360.PubMedCrossRefGoogle Scholar
  37. 37.
    Thomas PR, Tefft M, Compaan PJ, Norkool P, Breslow NE, D’Angio GJ: Results of two radiation therapy randomizations in the third National Wilms’ Tumor Study. Cancer 1991; 68: 1703–7.PubMedCrossRefGoogle Scholar
  38. 38.
    D’Angio GJ, Farber S, Maddock CL: Potentiation of x-ray effects of actinomycin D. Radiology 1959; 73: 175–177.PubMedGoogle Scholar
  39. 39.
    Sutow W, Thurman WG, Windmiller J: Vincristine (leucocristine) sulfate in the treatment of children with metastatic Wilms’ tumor. Pediatrics 1963; 32: 880–887.Google Scholar
  40. 40.
    Bellani FF, Gasparini M, Boanadonna G: Adriamycin in Wilm’s tumor previously treated with chemotherapy. Eur J Cancer Clin Oncol 1975; 11: 593–595.Google Scholar
  41. 41.
    Evans AE, Norkool P, Evans I, Breslow N, D’Angio GJ: Late effects of treatment for Wilms’ tumor. A report from the National Wilms’ Tumor Study Group. Cancer 1991; 67: 331–336.PubMedCrossRefGoogle Scholar
  42. 42.
    Von Hoff DD, Layard MW, Basa P, Davis Jr HL, Von Hoff AL, Rozencwig M, Muggio FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Int Med 1979; 91: 710–717.CrossRefGoogle Scholar
  43. 43.
    Green DM, Breslow NE, Moksness J D, D’Angio, GJ: Congestive heart failure following initial therapy for Wilms tumor. A report from the National Wilms tumor study. Pediatr Res 1994; 35: 161A.Google Scholar
  44. 44.
    Luttenegger TJ, Gooding CA, Fickenscher LG: Compensatory renal hypertrophy after treatment for Wilms’ tumor. Am J Roentgenol 1975; 125: 348–351.CrossRefGoogle Scholar
  45. 45.
    Walker RD, Reid CF, Richard GA, Talbert JL, Rogers BM: Compensatory renal growth and function in post-nephrectomized patients with Wilms’ tumor. Urology 1982; 19: 127–130.PubMedCrossRefGoogle Scholar
  46. 46.
    Wikstad I, Celsi G, Larsson L, Herin P, Aperia A: Kidney function in adults born with unilateral agenesis or nephrectomized in childhood. Pediatr Nephrol 1988; 2: 177–182.PubMedCrossRefGoogle Scholar
  47. 47.
    Shalet SM, Beardwell CG, Morris-Jones PH, Pearson D, Orrell DH: Ovarian function following abdominal irradiation in childhood. Br J Cancer 1976; 33: 655–658.PubMedCrossRefGoogle Scholar
  48. 48.
    Shalet SM, Beardwell CG, Jacobs HS, Pearson D: Testicular function following irradiation of the human prepubertal testis. Clin Endocrinol 1978; 9: 483–490.CrossRefGoogle Scholar
  49. 49.
    Li FP, Gimbrere K, Gelber RD, Sallan SE, Flamant F, Green DM, Heyn RM, Meadows AT: Outcome of pregnancy in survivors of Wilms’ tumor. JAMA 1987; 257: 216–219.PubMedCrossRefGoogle Scholar
  50. 50.
    Li FP, Yan JC, Sallan S, Cassady JR, Danahy J, Fine W, Gelber RD, Green DM: Second neoplasms after Wilms’ tumor in childhood. J Nat Cancer Inst 1983; 71: 1205–1209.PubMedGoogle Scholar
  51. 51.
    Breslow NE, Norkool PA, Olshan A, Evans A, D’Angio GJ: Second malignant neoplasms in survivors of Wilms’ tumor: A report from the National Wilms’ Tumor Study. J Natl Cancer Inst 1988; 80: 592–595.PubMedCrossRefGoogle Scholar
  52. 52.
    Breslow NE, Beckwith JB: Epidemiological features of Wilms’ tumor: Results of the National Wilms’ Tumor Study. J Natl Cancer Inst 1982; 68: 429–436.PubMedGoogle Scholar
  53. 53.
    Van Heyningen V, Bickmore WA, Seawright A, Fletcher JM, Maule J, Fekete G, Gessler M, Bruns GA, Huerre-Jeanpierre C, Junien C, Williams BRG, Hastie ND: Role for the Wilms tumor gene in genital development? Proc Natl Acad Sci USA 1990; 87: 5383–5386.PubMedCrossRefGoogle Scholar
  54. 54.
    Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE: WTI mutations contribute to abnormal genital system development and hereditary Wilms’ tumour. Nature 1991; 353: 431–434.PubMedCrossRefGoogle Scholar
  55. 55.
    Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D: Expression of the Wilms’ tumor gene WTI in the murine uro-genital system. Genes Dev 1991; 5: 1345–1356.PubMedCrossRefGoogle Scholar
  56. 56.
    Kreidberg JA, Sarlola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenish R: WT-1 is required for early kidney development. Cell 1993; 74: 679–691.PubMedCrossRefGoogle Scholar
  57. 57.
    Miller RW, Fraumeni JF, Manning MD: Association of Wilms’s tumor with aniridia, hemihypertrophy and other congenital abnormalities. N Engl J Med 1964; 270: 922–927.PubMedCrossRefGoogle Scholar
  58. 58.
    Leisenring WM, Breslow NE, Evans IE, Beckwith JB, Coppes MJ, Grundy P: Increased birth weights of National Wilms Tumor Study patients suggest a growth factor excess. Cancer Res 1994; 54: 4680–4683.PubMedGoogle Scholar
  59. 59.
    Niikawa N, Ishikiriyama S, Takahashi S, Inagawa A, Tonoki H, Ohta Y, Hase N, Kamei T, Kajii T: The Wiedemann-Beckwith syndrome; Pedigree studies on five families with evidence for autosomal dominant inheritance with variable expressivity. Am J Med Genet 1986; 24: 41–55.PubMedCrossRefGoogle Scholar
  60. 60.
    Aleck KA, Hadro TA: Dominant inheritance of Wiedemann-Beckwith syndrome: Further evidence for transmission of “unstable permutation” through carrier women. Am J Med Genet 1989; 33: 155–160.PubMedCrossRefGoogle Scholar
  61. 61.
    Koufos A, Grundy P, Morgan K, Aleck KA, Hadro T, Lampkin BC, Kalbakji A, Cavenee WK: Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 1Ip15.5. Am J Hum Genet 1989; 44: 711–719.PubMedGoogle Scholar
  62. 62.
    Coppes MJ, Bonetta L, Huang A, Hoban P, Chilton-MacNeill S, Campbell CE, Weksberg R, Yeger H, Reeve AE, Williams BRG: Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for non-disjunction or mitotic recombination. Genes Chrom Cancer 1992; 5: 326–334.PubMedCrossRefGoogle Scholar
  63. 63.
    Jadresic L, Leake J, Gordon I, Dillon MJ, Grant DB, Pritchard J, Risdon RA, Barratt TM: Clinicopathologic review of twelve children with nephropathy, Wilms tumor, and genital abnormalities (Drash syndrome). J Pediat 1990; 117: 717–725.PubMedCrossRefGoogle Scholar
  64. 64.
    Habib R, Loirat C, Gubler MC, Niaudet P, Bensman A, Levy M, Broyer M: The nephropathy associated with male pseudohermaphroditism and Wilms’ tumor (Drash syndrome): A distinctive glomerular lesion–report of 10 cases. Clin Nephrol 1985; 24: 269–278.PubMedGoogle Scholar
  65. 65.
    Stay EJ, Vawter G: The relation between nephroblastoma and neurofibromatosis (Von Recklinghausen’s disease). Cancer 1977; 39: 2550–2555.PubMedCrossRefGoogle Scholar
  66. 66.
    Simila S, Timonen M, Heikinnen E: A case of Mulibrey nanism with associated Wilms’ tumor. Clin Genet 1980; 17: 29–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Perheentupa J, Autio S, Leisti S, Raitta C, Tuuteri L: Mulibrey nanism, an autosomal recessive syndrome with pericardial constriction. Lancet 1973; ii:351–355.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Max J. Coppes
    • 1
  • Christine Campbell
    • 2
  • Bryan R. G. Williams
    • 2
  1. 1.Tom Baker Cancer Centre and University of CalgaryCalgaryCanada
  2. 2.Department of Cancer Biology Research InstituteCleveland Clinic FoundationClevelandUSA

Personalised recommendations